Non-small-cell lung cancer

Clinical three-dimensional conformal radiotherapy research using repeated computed tomography scans for field reduction in older non-small-cell lung cancer patients

Z. Z. Fu, Gu, T., Zhang, S. H., Cao, X. Y., Zhang, Q. H., Zhang, Y. Q., Hua, H. X., Yang, S., Li, P., and Zhang, Z., Clinical three-dimensional conformal radiotherapy research using repeated computed tomography scans for field reduction in older non-small-cell lung cancer patients, vol. 13, pp. 5343-5349, 2014.

This study investigated the curative and toxic effects of three-dimensional conformal radiotherapy (3D-CRT), using repeated CT scans for field reduction in older non-small-cell lung cancer (NSCLC) patients. 3D-CRT was administered to 36 older patients with NSCLC, and irradiation fields included the primary lesion and metastatic lymph nodes. After CT localization scanning, images were fed into a treatment planning system to delineate the gross tumor volume (GTV)1 and prepare Plan 1.

Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment

M. X. Zhang, Tan, W., Zhang, R. X., Tian, Y. L., Gao, H. M., Gao, Z., Zhang, N., Zhao, J. Q., Jia, Y. F., and Wang, Y. S., Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment, vol. 13. pp. 8657-8660, 2014.

The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib.

Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China

L. Yang, Shi, G. L., Song, C. X., and Xu, S. F., Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China, vol. 9, pp. 765-771, 2010.

Monocyte chemoattractant protein 1 (MCP-1) is an important chemokine that has a dose-dependent anti-tumoral effect. Polymorphism in the MCP-1 distal regulatory region (-2518A/G) can affect the level of MCP-1 expression. We examined the polymorphisms of 112 unrelated patients with non-small-cell lung cancer (NSCLC) and 82 unrelated healthy controls of Han nationality in North China using PCR-RFLP. We found that the distributions of AA, AG and GG genotypes of MCP-1-2518 were significantly different in NSCLC patients compared to controls (X2 = 10.106, P = 0.006).

Subscribe to Non-small-cell lung cancer